Investigation of the mechanism and enzyme responsible for the conversion of cotinine back to nicotine using human plasma
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 168
- Locations
- 1
- Primary Endpoint
- The study will estimate and compare the plasma levels of SOD,CAT,GPx in smokers and non somokers
Study Overview
Brief Summary
Our early clinical study (ICMR Clinical Trial Registry India Registration No: CTRI/2022/12/048600). with smoker’s plasma samples was conclusively prove that the nicotine convert cotinine can be convert back to nicotine using Antioxidant (Ascorbic acid). The study result was the first time in the literature and the exact reason for the conversion of cotinine back to nicotine is uncertain. Interestingly, the conversion of cotinine back to nicotine was not happening in plasma without ascorbic acid or in water, therefore it indicates that some Antioxidant enzyme in plasma will involve and cotinine back to nicotine. Therefore, in this study attempt to explore the enzyme response for the conversion of cotinine back to nicotine in human plasma.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18.00 Year(s) to 60.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Chronic smoker
- •patients above 18 years old
- •consumer of other tobacco products such as chewed products, electronic cigarette, etc.
Exclusion Criteria
- •Patients with no smoking effect
- •Pregnant women
- •Patients taken alcohol within 24 hours.
Outcomes
Primary Outcomes
The study will estimate and compare the plasma levels of SOD,CAT,GPx in smokers and non somokers
Time Frame: 6 months
Secondary Outcomes
- mechanism of the conversion of cotinine back to nicotine in presence of ascrobic acid(6 months)
Investigators
Dr Murugesan Arumugam
Sri Ramachandra Institute of Higher Education and Research, Chennai-600116